IFNG and central nervous system cancer: These include the target of epigenetic derangements that are known to contribute to the pathogenesis of glioma and to its highly immunosuppressive microenvironment, downregulating the tumor expression of different immune molecules, including major histocompatibility complex (MHC) class I and class II proteins, affecting antigen presentation, and of STING, with a subsequent effect on IFN-γ production and cytokine/chemokine release [16].